Exela Pharma Sciences, LLC, Lenoir, NC
Is Exela Pharma Sciences, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B, with FDA’s note “De-registered as an outsourcing facility”.
Does Exela Pharma Sciences, LLC hold a North Carolina pharmacy license?
State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks. The Delaware Division of Professional Regulation also lists nonresident license AD-0000004 for Exela Pharma Sciences, LLC, LENOIR, NC, status Expired, license AD-0000044 for Exela Pharma Sciences, LLC, LENOIR, NC, status Expired, license AD-0010083 for Exela Pharma Sciences, LLC, LENOIR, NC, status Expired and license AD-0010084 for Exela Pharma Sciences, LLC, LENOIR, NC, status Expired, as of Nov 10, 2026.
Has Exela Pharma Sciences, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 2 warning letters (Apr 8, 2021 and Jul 2, 2025), 1 warning letter close-out (Apr 30, 2021), 1 untitled letter (Dec 2, 2021) and 1 FMD-145 letter (Mar 7, 2019) for Exela Pharma Sciences, LLC. State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Exela Pharma Sciences, LLC
- Location
- Lenoir, NC
- Type as FDA labels it
- 503B
- FDA’s note
- De-registered as an outsourcing facility
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 2
- Latest action on that page
- Jul 2, 2025
- FDA Data Dashboard inspections
- 12 inspections: 1 OAI, 5 VAI, 6 NAI; 5 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 28 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Exela Pharma Sciences, LLC, a 503B facility, with 7 dated actions.
| Document | |||
|---|---|---|---|
| Jul 2, 2025 | Warning letter | Warning Letter (07/02/2025) | fda.gov |
| Nov 15, 2024 | Form 483 | 483 Issued 11/15/2024 | fda.gov |
| Dec 2, 2021 | Untitled letter | Untitled Letter Issued 12/02/2021 | Not linked by FDA |
| Apr 30, 2021 | Warning letter close-out | Warning Letter Closeout Issued 04/30/2021 | Not linked by FDA |
| Apr 8, 2021 | Warning letter | Warning Letter (04/08/2021) | fda.gov |
| Jul 18, 2019 | Form 483 | 483 Issued 07/18/2019 | fda.gov |
| Mar 7, 2019 | FMD-145 letter | FMD-145 Letter Issued 03/07/2019 | Not linked by FDA |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Exela Pharma Sciences LLC, Lenoir, NC (FEI number 3008563008), matched to this page by exact name, city and state. It lists 12 inspections: 1 OAI, 5 VAI, 6 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Nov 15, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3008563008 | 1256957 |
| Jul 18, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3008563008 | 1096634 |
| Dec 19, 2018 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3008563008 | 1081405 |
| Sep 11, 2018 | No Action Indicated (NAI) | Bioresearch Monitoring (Drugs) | 3008563008 | 1067755 |
| Sep 28, 2017 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3008563008 | 1026858 |
| Jun 8, 2016 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3008563008 | 988490 |
| Nov 21, 2014 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3008563008 | 906470 |
| Aug 28, 2014 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3008563008 | 893626 |
| Apr 12, 2013 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3008563008 | 849770 |
| Jan 20, 2012 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3008563008 | 766906 |
| Sep 2, 2011 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3008563008 | 750589 |
| Dec 10, 2010 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3008563008 | 701088 |
Form 483s FDA has published for this site
- Nov 15, 2024: Form 483 to Exela Pharma Sciences LLC, published Feb 14, 2025. fda.gov
- Jul 18, 2019: Form 483 to Exela Pharma Sciences LLC, published Oct 18, 2019. fda.gov
- Sep 28, 2017: Form 483 to Exela Pharma Sciences LLC, published Dec 9, 2019. fda.gov
- Dec 23, 2016: Form 483 to Exela Pharma Sciences LLC, published Jan 17, 2024. fda.gov
- Jan 23, 2016: Form 483 to Exela Pharma Sciences LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 28 numbered observations in all, across 3 inspections ending Sep 28, 2017 to Nov 15, 2024. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 4, 2024 to Nov 15, 2024: 15 observations
- Firm on the cover
- Exela Pharma Sciences LLC, 1245 Blowin Rock Blvd, Lenoir, NC 28645
- FEI number
- 3008563008
- Establishment type on the cover
- Outsourcing Facility/ Sterile Drug Manufacturin Facility
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up. Specifically,
503B Outsourcing facility
A. <Redacted B4> me dia lot <Redacted B4> used for release sterility testing of Sodium Acetate failed initial growth promotion testing. Your firm invalidated two tests of this lot of media and passed the third test without scientific justification. The initial test was performed on <Redacted B4> retested on <Redacted B4> and retested <Redacted B4> with passing results on <Redacted B4>. Your firm's investigation, QE-000487, states that human performance was determined to be the root cause of the failed testing events. Your firm stated that there was no product impact based on this investigation. Your firm did not document any specific human error identified when testing the FTM media FTM Lot <Redacted B4> was used in sterility testing of Sodium Acetate lot <Redacted B4> and <Redacted B4> your firm released these lots of Sodium Acetate for distribution as follows:
r
In addition, the following other test media were inad. ...
Observation 2
The responsibilities and procedures applicable to the quality control unit are not fully followed. Specifically,
Drug Manufacturer
Your firm filled Sodium Bicarbonate Injection, USP lot <Redacted B4> ANDA 211091, in Augusta facility grade A, B, C, and D areas that were tagged as "QA HOLD". This lot was filled in Augusta facility on 11/6/2024. Quality hold was placed on the entrance to the <Redacted B4> line on <Redacted B4>. The quality hold was placed on the room while waiting for <Redacted B4> EPA certification to be completed and reviewed.
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed. Specifically,
Drug Manufacturer
A. Your firm failed to adequately perform Disinfectant Efficacy Studies for <Redacted B4> and <Redacted B4> on Sterile Nitrite Gloves, RPT-002136, Version: 1.0 Effective Date: 24 March 2022. No contact time was documented for the sterile nitrile glove study performed and a dilution error was carried over the repeated study • fied as not impacting the study due to a <Redacted B4> on reduction (Log .<Redacted B4> ather than Log <Redacted B4> <Redacted B4> log reduction was attributed to a lower bacterial concentration.
Drug Manufacturer
(b) (4)
B. Your firm has not demonstrated that isinfectant is adequately used. For example, Surface Disinfectant Efficacy Studies contracted to challenge disinfectant efficacy testing of <Redacted B4> against Candida albicans did not meet the <Redacted B4> criteria for test surfaces <Redacted B4>. The disinfectant criteria passed criteria for all other surfaces challenged in the disinfectant efficacy study. ...
Observation 4
503B Outsourcing Facilitv and Drug Manufacturer
Your firm failed to perform contemoraneous two-person check during reading and data entry of environmental <Redacted B4> plates in the <Redacted B4> system. A single operator reads environmental plate counts takes pictures ofpositive counts (no pictures are taken of negative counts), enters results in the <Redacted B4> system and later results are reviewed and verified by QC personnel. There is no assurance that the operator has entered data accurately (missed or misread plates counts) at time ofreading. In addition, miscounted plates were observed in the microbiology lab on 11/6/2024. Miscounted colony forming units are as follows:
faile
~J~J~,~~J;~rm
Sample date
Sample type
Number of Colony Forming Units cfu on late
Analyst count
(b) (4) (b) (4)
Plate number
Sample location
Active viable air
lOcfu
8cfu
Active viable air
llcfu
lOcfu
Active viable air
4cfu
3cfu
Observation 5
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel. Specifically,
Drug Manufacturer / <Redacted B4>
A. Your firm failed to generate accurate and complete records in a legible, original or a true copy of electronic records suitable for inspection and review. During the implementation <Redacted B4> System, version <Redacted B4> completed on <Redacted B4> under the following change controls:
(b) (4)
(b) (4) (b) (4)
# <Red acted B4> and QE-000194 <Redacted B4> for Phase <Redacted B4> b. CR-12459 <Redacted B4> for Phase <Redacted B4> c. QE-000584 <Redacted B4> for Phase <Redacted B4> The affected data transition from <Redacted B4> system, during Phase <Redacted B4> and completed on <Redacted B4> was noted that the format used to present laboratory investigations, deviations, change controls, and other critical quality documentation is not conducive to effective review. The information presented is displayed in metadata format in a tabular layout, which does not assure that the data is readable and complete.
a. Change Con trol
(b) (4)
B. ...
Observation 6
The calibration of instruments and recording devices is not done at suitable intervals in accordance with an established written program. Specially,
Drug Manufacturer <Redacted B4>
A. Calibration certificates for the Analytical balances (Asset ID# QC2209 and Asset ID# QC2493 and Top loading balance (Asset ID# <Redacted B4> located in the QC Chemistry Laboratory, were found to be deficient. The reproducibility testmfue calibration certificates for these balances do not meet the required specifications to ensure suitability of the balances before use. These analytical and top loading balances are used for weighing reference standards and solution preparation for testing of raw materials, in-process, and finished products.
B. Analytical balance, (Asset ID# QC2209), located in the QC Chemistry Laboratory was observed to have poor maintenance (i.e. appeared to have rust/corrosion, displayed defective side doors that did not open as expected). This analytical balance is used for weighing reference standards and samples used for evaluation and release of manufactured products that use data generated by analytical balance (i.e. raw data weights).
C. ...
Observation 7
Laboratory records do not include complete records of any testing and standardization of laboratory standard solutions. Specifically,
Drug Manufacturer
Your firm failed to have analytical data to support the stability of Resolution Solution used during the sample analysis of a sterile product identified as: Tranexamic Acid Injection, 10mg/mL, 100 mL IV Bag (i.e. Lot# <Redacted B4> Released on: 13 AUG 2024. According to laboratory record (Book: <Redacted B4> the resolution stock solution was prepared in <Redacted B4> and it has been used for the evaluation and further release of manufactured batches of this Tranexamic Acid Injection. This resolution solution is a combination of Tranexamic Acid Related <Redacted B4> and Tranexamic Acid for which the Tranexamic Acid standard solution has been identified as stable for <Redacted B4> Document: QCMET-000179). Your firm indicated that as per SOP-QC-000075: "Procurement, Receipt, Storage, and Expiration Dating of Laboratory Chemicals", Document Version 2.0, Effective Date: 09 Feb 2021. ...
Observation 8
Established laboratory control mechanisms are not followed and documented at the time of performance. Specifically,
l
Drug Manulacturer <Redacted B4>
A. Retain samples for commercial products and raw materials were not stored in their designated locations as required by SOP-000024: "Quality Assurance Retain Manag_e-ment", Document Version: 8.0, Effective Date: 16 Mav 2024. Samples identified i (b) (4)inventory log as being located on the-(b) (4)andl (b) (4)!shelves were not found. Your Retain 7Manager was unable to locate it. Additionally, the room was cluttered, with retain samples and raw materials stored in a packed manner, which may have contributed to the difficulty in locating the samples and increased the risk ofmisplacement or improper storage. For example:
Product Name
Exela Lot Number
Qty Storag e Location l Pentamidine Isethionate for Injection ( l 50mg/mL,2mL fill)300mg/vial, l0mL Vial (Finish Drug Product)
(b) (4)
Streptomycin for Injection, USP, 200mg/mL, lg/vial, l0mL vial (Finish Drug)
20mL Vial, Clear, Type I Glass Tube (Raw Material)
B. Your firm failed to have GMP equipment segregated from Research and Development (R&D). ...
Observation 9
There is no written testing program designed to assess the stability characteristics of drug products. Specifically,
503B Outsourcing Facility
Your firm does not have stability data to support a 6-month expiration date for Sodium Chloride injection 0.9% Injection, USP packaged in 500mL polypropylene IV bags. Your firm produced <Redacted B4> batches of Sodium Chloride in IV bags in and placed them on stability for potential 503B compounding. This study was performed using package size with a fill volume of <Redacted B4> this study data was produced using different equipment, compounding/filling rooms, and packaging configurations than the current Sodium Chloride Injection 0.9%, USP being compounded at your firm. The current Sodium Chloride Injection 0.9% USP batches are packaged in 500mL polypropylene IV bags with a 500mL fill volume and a batch size of <Redacted B4> your firm used the data from the 2017 study to justify a 6-month expiration on the current Sodium Chloride Injection 0.9% USP being compounded. In addition, your firm has not performed any sterility testing on Sodium Chloride IV bags currently being compounded.
Observation 10
Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions. Specifically,
503B Outsourcing Facility <Redacted B4>
nspecti on qualification <Redacted B4> is inadequate.
A.
Your firm's i
i.
Your firm' s visual inspection kit used during qualification is not representative of the visual inspection process. Your firm's visual inspection <Redacted B4> is comprised of <Redacted B4> vials of a variety of vials sizes ranging from <Redacted B4>. These vials also contain a variety of products depending on the vial size. During visual inspection of a production batch the visual inspection process is performed on <Redacted B4> and <Redacted B4>
Your fi rm's qualification <Redacted B4> does not contain all defects found in production lots. For example, your firm's defect classifications are missing from the following vial qualification <Redacted B4>. The clear vial inspection <Redacted B4> does not include critical defects; gross high fill and gross low fill. The clear vial inspection kit does not include major defect, empty unit. ...
Observation 11
The statistical quality control criteria fail to include appropriate rejection levels. Specifically,
(b) (4) 503B Outsourcing Facility
Your firm has a <Redacted B4> overall reject limits for visual inspection, individual defect categories do not have reject limits. Your firm does not open investigations unless an overall <Redacted B4> visual inspection reject rate is reached. Your firm rejected 69 cracked vials, which are considered a critical defect, from lot <Redacted B4> of Sodium Acetate Injection, l00mL vials without opening any investigation. Your firm also rejected 79 cracked vials from lot <Redacted B4> of Sodium Acetate Injection, 100 mL vials without opening any investigation.
Observation 12
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components, drug product containers and closures before disposition. Specifically,
Drug Manufacturer
Your firm failed to properly handle reject drug products. For the example, during the inspectional walkthrough of your Reject Room (Reject Cage), I found you did not have a logbook or a physical inventory in place of materials stored in cage. Your Quality Assurance Manager, stated material stored in cage is verified <Redacted B4>. However, it is not documented nor there is written instructions for <Redacted B4> on your procedure."Handling of Rejects, SOP-000035 Doc Version: 4.0 Effective Date: 01 Aug 2024". Additionally, In-process rejects or finished rejects cannot be physically identified due to incorrect labels affixed on rejects. Your SOP lacks a defined list of reject materials that can be stored in the area. For example, Media Fill rejected samples were found in the area but not included as one that should be in that area. ...
Observation 13
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the receipt, identification, storage, and withholding from use of components, drug product containers, and closures pending sampling, testing, or examination by the quality control unit before release for manufacturing or packaging. Specifically,
Drug Manufacturer
Your firm failed to record storage conditions during the receipt of Active Pharmaceutical Ingredients (APis). There is no assurance that drug substance has been kept under the right temperature conditions before and after receipt. During review of the Raw Material Disposition Report (FRM-000046 Doc Version: 12.0, Effective Date: 28 Dec 2023, Controlled Copy ID# CC-FRM-000046 <Redacted B4> found storage conditions are not indicated as required in the report. Warehouse operator stated that raw material is not received with a data logger and no time entry is recorded upon receipt of drug substance (only date). Manufacturer's label on raw material indicates raw material API should be kept refrigerated at <Redacted B4>
Observation 14
The labels of your outsourcing facility's drug products are deficient.
503B Outsourcing Facility
1. The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A). Specifically, the following information is not found on your drug product labels: Examples of your drug product labels that do not contain this information, include but are not limited to:
a. The dosage form
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A). Specifically, the following information is not found on your drug product labels: Examples of your drug product labels that do not contain this information, include but are not limited to:
• Midazolam HCl in 0.8% Sodium Chloride 50mL
• Midazolam HCl in 0.8% Sodium Chloride 100mL
Observation 15
Written production and process control procedures are not followed in the execution of production and process control functions. Specifically,
(b) (4) Your firm's process validation for <Redacted B4>,used in <Redacted B4> Sodium Injection 0.9%, USP were performed using <Redacted B4> and not using product. There is no data to assure that the sterilization process is effective when the <Redacted B4> is performed on compounded drug products.
Inspection Jun 10, 2019 to Jul 18, 2019: 7 observations
- Firm on the cover
- Exela Pharma Sciences LLC, 1245 Blowing Rock Blvd, Lenoir, NC 28645-3618
- FEI number
- 3008563008
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 60 Eight h St reet NE Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically, on 6/ 13/ 2019, during the "Compounding" and " Filling" of Norepinephrine Bitartrate Injection, USP, Lot Number PROT-000656, I observed poor aseptic technique. For example,
a) During "Compounding" operations in Room 138 (Class 100,000):
i.
Operators frequently placed themselves over the open product. They reached directly across the product to reach equipment on the wall and I observed an operator's hair, covered with a hair-net, directly above the open product while she adjusted the mixing bag.
ii.
The equipment used to monitor <Redacted B4> was not disinfected before or in-between measurements, which required the <Redacted B4> ,be submerged in the compounded product and the <Redacted B4> to rest on the interior surface of the <Redacted B4> used for additions.
I
b) During "Filling" operations in Room 139 (Class 10,000) and Fill Class 100):
i.
During needle installation, I noted the operator responsible for passing the needles to the other operator had his head slightly inside the Class 100 RABS (restricted access barrier system). ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
a) EM excursions are often not associated with potentially impacted products and lot numbers. Corrective actions do not include cleaning or verification of cleaning, which is of particular concern when an investigation identifies a spore-forming organism.
b) The environmental data being capt ured by D) -(4) I) is not routinely reviewed, tracked, or trended . {I>) (4J is used to monitor t emperature, relative humidity, differential pressure, and tot al particles. The syst em is only reviewed when alarms trigger due to an excursion event for differential pressure, temperature, and relative humidity.
i. Per SOP-OP-000021, Monitoring of Differential Pressures for Clean room Areas, a (b) <4l report will be printed and attached t o each batch record for filling activities. This is not
being performed. No similar procedures exist which require temperature and relative humidity to be printed, reviewed, and attached to applicable batch records. c) Personnel do not always use best practices during finger-plating. ...
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically,
a) During a media fill for Protocol 2018-PQ-053, an incubated vial exhibited growth and was inappropriately reclassified as non-integral, invalidating the positive result. The vial was part of Lot XM HA1806 and had been segregated as an integral reject prior to incubation due to it missing an over-seal but having a fully-seated stopper. The investigation found no obvious breach in the vial integrity yet concludes the vial should not have been included as an integral reject because it was missing its over-seal. The growth was not identified due to it s reclassification. The investigation lacks scientific justification to invalidate the growth observed during the media fill.
Lot XM HA1806 and had been segregat ed as an integral reject prior to incubation due to it missing an over-seal but having a fully-seat ed st opper. The investigation found no obvious breach in the vial integrity yet concludes the vial should not have been included as an integral
reject because it was missing its over-seal. ...
Observation 4
Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
Specifically, the IV bags used for Sodium Chloride 0.9% injection, a <Redacted B4> product, are not purchased or rendered sterile, pyrogen-free, or particle-free.
Observation 5
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically, during review of quality investigations, numerous concerns were observed. For example, regarding Sodium Bicarbonate (84 mg/ml ), Lot BM HG1802, a 503B product which was "Compounded" on 7/ 31/2018:
a) DEV-00238 was initiated on 7/31/ 2018 due to 4 alert and action level alarms for <Redacted B4> particulates during the first <Redacted B4> of filling, though the <Redacted B4> records indicate the alarms were triggered for bot <Redacted B4> and <Redacted B4> sized particles. Batch documentation indicates there were numerous alarms but does not provide the approximate time every alarm sounded nor the activity which was being performed, if any, at the time of each alarm. Additionally, operators 64 noticed a drip from<) <>needles, specifically, needle <Redacted B4> when the filler was stopped. It states there was no drip during production. There is no indication the issue was resolved and the aerosolization of dried product due to the fill-needles dripping was not considered as part of the investigation. ...
Observation 6
Batch production and control records do not include complete information relating to the production and control of each batch.
Specifically,
a) During review of the batch documentation for Erythromycin Lactobionate (500 mg/vial), 20 ml vial, 4(b)(l batch, Lot CMHG1822, "Compounded" on 7/ 19/ 2018, which has not been released, I not ed the following:
i.
During "Compounding" Step <Redacted B4> the operators did not follow the recommended instructions for the addition of the erythromycin base, an API, by adding it in <Redacted B4> divisions with a <Redacted B4> stir time for each division . The recommended method for API addition would result in a minimum of <Redacted B4> and this batch had the erythromycin added over <Redacted B4>. IAdditionally, later in this step, the mix start-and end-time are recorded, but there is no verification the mix time does not exceed the <Redacted B4> maximum mixing time specified in bold within the instructions.
ii.
There is no verification the unfiltered, bulk solution was maintained at less than <Redacted B4> prior to being <Redacted B4> into the holding bag/ vessel. ...
Observation 7
Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, the Class 100 <Redacted B4> Exela Asset OP4015.018, used to provide ISO 5 grade air during <Redacted B4> vial transfer, has not been fully certified. The <Redacted B4> also referred to as the <Redacted B4> or the Portable Class 5 Enclosure, has failed for <Redacted B4> testing during the previous two certifications, performed in August 2018 and February 2019. The certification report indicates the acceptance criteria is NLT <Redacted B4> air changes per hour. The results were 172 air changes per hour and 223 air changes per hour, respectively.
Additionally, SOP-VA-000002, Certification of HEPA Filters, indicates the <Redacted B4> should be tested per the <Redacted B4> test with an acceptance criterium of <Redacted B4> per minute at <Redacted B4> from the filter face. The previous two certifications were performed for air changes per hour.
Inspection Sep 19, 2017 to Sep 28, 2017: 6 observations
- Firm on the cover
- Exela Pharma Sciences LLC, 1245 Blowing Rock Blvd
- FEI number
- 3008563008
- Establishment type on the cover
- O utsourcing F acility Lenoir, NC 28645 -3618
- FDA district office on the cover
- E Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
There was a failure to handle and store components and drug product containers at all times in a manner to prevent contamination.
Specifically,
a) Your firm cannot ensure that materials, products, and/or samples are kept at a controlled room
temperature.
l. Your firm currently transports raw materials and finished product between their <Redacted B4> facilities via a company truck that is not temperature controlled.
2. Your firm currently transports raw material samples and finished product samples <Redacted B4> between their <Redacted B4> facilities via employees' personal vehicles. Your firm does not have a standard practice and/or procedure specifying who can transport manufacturing materials and products (in Ziploc bags) and does not maintain records for time in transport. Additionally, these samples are placed in a Ziploc bag with a label on the bag, without any seal to secure the samples in the Ziploc bag during transport.
3. Your firm cannot ensure that microbiology samples are maintained at controlled room temperature. Your firm monitors temperature using one temperature probe in the microbiology laboratory, which consists of <Redacted B4> cleanrooms without a door. ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
a) Your firm did not certify that the ISO-classification of the ISO-classified areas are met under
dynamic conditions prior to the release and distribution of the following lots of Sodium
Bicarbonate Injection 84mg/mL (lmEq/mL), 50mL vials:
L. Lot #BMHG J709, compounded/filled 7 /24/17, released/distributed 8/1 5/l7 2. Lot #BMHHl 70l, compounded/filled 8/15/17 released/distributed 9/26/17 b) Your firm monitors pressure differentials via the <Redacted B4> Magnehelic gauges for the<Redacted B4> of the <Redacted B4> (ISO 5 area) before and after production, but not during production.
Observation 3
Routine checking of electronic equipment is not performed according to a written program designed to assure proper performance.
Specifically, your firm does not challenge the <Redacted B4> system that verifies lot numbers/expiration dates and barcodes, prior to use of the system. Currently, your firm <Redacted B4> the <Redacted B4> system, <Redacted B4> packaging and labeling operation, <Redacted B4> to ensure that it will pass if a label with the correct lot number, expiration date, and barcode is read. However, no challenge is conducted to ensure that the system can detect if there is a label with an incorrect lot number, expiration date, and/or · barcode. Your firm only challenges the <Redacted B4> system at the time of its original qualification, on 1/4/14, when it was <Redacted B4> facility.
Observation 4
The results of the examination of the packaged and labeled products were not documented in the batc h production or control records.
Specifically, operators on the packaging and labeling line do 100% visual examination of vial labels and QA personnel do I 00% visual inspection of carton labels and for the presence of the vial in the carton prior to closing the carton. However, the results of these inspections are not recorded in the batch record or elsewhere.
Observation 5
Strict control is not exercised over labeling issued for use in drug product labeling operations.
SpecificaJly,
a) Your firm has not validated the electronic system used to create labels.
1. Your firm is creating labels through the <Redacted B4> which is installed on an undetermined number of computers at Exela.
2. On 9/20/17, I observed PDF labels for Sodium Bicarbonate Injection 8~mL lmEq/mL" 50mL vials, generated in <Redacted B4> being stored on a <Redacted B4>
3. Access to this folder could not be determined, as your firm changed the location, name, and permissions of 503B Labels folder during the inspection without documenting this change. b) Your firm docs not define a specified maximum timeframe, either in practice or in procedure, that labels can remain in the QA Office/Staging Area, which is not temperature controlled, prior to their utilization in packaging and labeling operations.
Observation 6
The labels of your outsourcing facility's drug products are deficient.
Specifically, labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l O)(A), as the quantity or volume is not on your drug product labels (vials). Currently, the volume is on your drug product containers (cartons). Vial labels for Sodium Bicarbonate Injection, 84mg/mL (lmEq/mL), SOmL vials, do not contain this information.
Linked 483s whose text is not shown
- Jan 23, 2016: FDA document 90320: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0000004 | Outsourcing Facility-Distributor | Exela Pharma Sciences, LLC | LENOIR, NC | Expired |
| AD-0000044 | Outsourcing Facility-Distributor | Exela Pharma Sciences, LLC | LENOIR, NC | Expired |
| AD-0010083 | Outsourcing Facility-Distributor | Exela Pharma Sciences, LLC | LENOIR, NC | Expired |
| AD-0010084 | Outsourcing Facility-Distributor | Exela Pharma Sciences, LLC | LENOIR, NC | Expired |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Delaware Division of Professional Regulation license file
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.